Evidence-Based Complementary and Alternative Medicine / 2020 / Article / Tab 2

Review Article

Efficacy and Safety of Duhuo Jisheng Decoction for Postmenopausal Osteoporosis: A Systematic Review and Meta-Analysis

Table 2

Characteristics of the included trials.

Study IDSampleAge (years, mean)InterventionsDurationOutcomes
Size (T/C)TCTCIn months

Lehui [11]100 (50/50)54.3 ± 3.254.8 ± 3.5DHJSDAlendronate (10 mg, qd, po)3
Yumei [12]60 (30/30)64.0 ± 6.265.0 ± 3.3DHJSD + controlZoledronic acid (4 mg, Q20 d, ivgtt)3①, ②, (a), ④, ⑤, and ⑥
Shangzhi and Juntao [13]70 (35/35)63.0 ± 3.364.0 ± 6.2DHJSDAlendronate (70 mg, qw, po)3①, ②, (a), ③, and ④; NBAP
Jinwei et al. [14]120 (60/60)67 ± 566 ± 6DHJSD + controlCaltrate D (600 mg, qn, po)3①, ②, (a, b), ④, ⑤, ⑥, and ⑦
Shaofeng [15]100 (50/50)58.87 ± 11.0858.64 ± 12.21DHJSD + controlZoledronic acid (5 mg, -, ivgtt)12①, ②, ③, and④
Keming et al. [16]60 (30/30)57.357.3A : DHJSD + controlC: zoledronic acid (4 mg, Q30 d, ivgtt)12①, ②, (a), ③, ④, and ⑦
Keming et al. [16]60 (30/30)57.357.3B : DHJSDC: zoledronic acid (4 mg, Q30 d, ivgtt)12①, ②, (a), ③, ④, and ⑦
Yang et al. [17]80 (40/40)53.69 ± 7.7652.82 ± 7.93DHJSD + controlCaltrate D (600 mg, 1-2 tablets, qn, po),3①, ②, (a, b), and ③; CTX

Note. ①, clinical effectiveness; ②, BMD (a, lumbar spine and b, femoral neck); ③, BGP; ④, E2; ⑤, P; ⑥, Ca; and ⑦, ALP, the information is lost; NBAP, bone alkaline phosphatase; CTX, c-terminal crosslinking telopeptide.

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.